Name: Oxfendazole
Brand: Selleck Chemicals
SKU: S1830
Availability: InStock
Rating: 5 (1 reviews)

Jump to

Quality Control

Batch: S183001 DMSO]10 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 100%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

100

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Reverse Transcriptase HIV HCV Protease
Other Parasite Products	Diminazene Aceturate Oxibendazole Arteether Diclazuril Fenbendazole α-santonin Nicarbazin Pyrantel Pamoate Carica Papaya Fruit Extract Torreyae Semen Extract

Solubility

In vitro
Batch:

DMSO : 10 mg/mL (31.71 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	315.35	Formula	C₁₅H₁₃N₃O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	53716-50-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RS-8858,Fenbendazole sulfoxide			Smiles	COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3

Mechanism of Action

In vivo

Oxfendazole (OX) induces not only mRNA expression of phase I enzymes Cyp1a1, Cyp1a2, but also Nrf2-regulated phase II enzymes such as Gpx2, Nqo1, Yc2, Akr7a3 and Gstm1 in rats, presumably due to an adaptive response against OX-induced oxidative stress. This compound enhances oxidative DNA damage (as assessed by 8-hydroxydeoxyguanosine; 8-OHdG) and lipid peroxidation (as assessed by thiobarbituric acid-reactive substances; TBARS) in rats. This chemical administered at the therapeutic dose (4.5 mg/kg) and at the highest dose (22.5 mg/kg) increase 1.54- and 2.36-fold the total liver microsomal cytochrome P450 and more particularly the isoenzyme P450IA2 (95% and 184% increases) in rabbit liver. It induces a mutagenic effect in all tested cell types. It exhibits embryotoxicity including teratogenicity. It induces a disturbance in the different biochemical contents of all tested tissues in mice. This compound increases the incidence and multiplicity of altered foci (4.0- and 3.6-fold, respectively) and hepatocellular adenomas (HCAs) (3.0- and 5.5-fold, respectively). This treatment induces 5.2- and 5.6-fold increases in the number of proliferating cell nuclear antigen (PCNA)-positive cells and single-stranded DNA (ssDNA)-positive cells in HCAs compared with the surrounding tissue, respectively. It and its sulphone metabolite attain a significantly higher plasma concentration and remain much longer in plasma compared with fenbendazole (FBZ) and albendazole (ABZ) and their respective metabolites in dogs.

References

[1] https://pubmed.ncbi.nlm.nih.gov/18754104/
[2] https://pubmed.ncbi.nlm.nih.gov/2039538/
[3] https://pubmed.ncbi.nlm.nih.gov/16597420/

[4] https://pubmed.ncbi.nlm.nih.gov/20502879/
[5] https://pubmed.ncbi.nlm.nih.gov/17673370/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06367361	Not yet recruiting	Fascioliasis	Universidad Peruana Cayetano Heredia\|National Institute of Allergy and Infectious Diseases (NIAID)	July 2024	Phase 2
NCT04920292	Completed	Filariasis	Swiss Tropical & Public Health Institute\|Ifakara Health Institute\|Drugs for Neglected Diseases	April 21 2022	Phase 1
NCT02636803	Withdrawn	Helminthiasis	Johns Hopkins Bloomberg School of Public Health\|Universidad Peruana Cayetano Heredia	November 2019	Phase 2
NCT03035760	Completed	Helminthic Infection	National Institute of Allergy and Infectious Diseases (NIAID)	May 12 2017	Phase 1
NCT02234570	Completed	Neurocysticercosis	National Institute of Allergy and Infectious Diseases (NIAID)	November 17 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Oxfendazole Parasite inhibitor

Chemical Structure

Molecular Weight: 315.35